William Wood

Gary Nachman

Leland Gershell

Anthea Li

Denis Reznik

Dennis Ding

Eduardo Martinez-Montes

Robert Sassoon

Yi Chen

- Veru Inc. announced the pricing of a public offering including **1,400,000 shares of common stock**, pre-funded warrants to purchase up to **7,000,000 shares**, and accompanying Series A and Series B warrants, each to purchase up to **8,400,000 shares** of common stock.  **[863894_0001193125-25-258565_d59421dex51.htm:0]** **[863894_0001193125-25-258565_d59421dex11.htm:0]** **[863894_0001193125-25-258565_d59421dex11.htm:1]** 
- The combined public offering price for each share of common stock with accompanying warrants is **$3.00**, and for each pre-funded warrant with accompanying warrants is **$2.999**.  **[863894_0001193125-25-258565_d59421dex992.htm:1]** 
- The offering is expected to generate approximately **$25.2 million** in gross proceeds, with potential additional gross proceeds of approximately **$50.4 million** if all warrants are exercised in cash.  **[863894_0001193125-25-258565_d59421dex992.htm:1]** 
- Net proceeds from the offering will primarily fund the development of **enobosarm**, focusing on Phase 2b PLATEAU clinical study activities, as well as working capital and general corporate purposes.  **[863894_0001193125-25-258565_d59421dex992.htm:1]** **[863894_0001193125-25-258565_d59421dex991.htm:1]** 
- The Series A warrants have an exercise price of **$3.00** and terminate on **October 31, 2030**.  **[863894_0001193125-25-258565_d59421dex42.htm:1]**  The Series B warrants also have an exercise price of **$3.00** and terminate on the earlier of **October 31, 2028**, or 45 days after a specific milestone event related to enobosarm clinical data and stock price performance.  **[863894_0001193125-25-258565_d59421dex43.htm:1]**

Veru Inc. Prices Public Offering of Common Stock and Warrants

- Veru Inc. priced an underwritten public offering of common stock, pre-funded warrants, and accompanying Series A and Series B warrants, with an expected closing date of **October 31, 2025**.  **[863894_9c0b793571da4d70bc46727eaf9d5ac6_0]** 
- The offering is anticipated to generate approximately **$25.2 million** in gross proceeds for Veru, with potential for an additional **$50.4 million** if all warrants are exercised.  **[863894_9c0b793571da4d70bc46727eaf9d5ac6_0]** 
- Net proceeds will be primarily allocated to fund the development of **enobosarm**, specifically for Phase 2b PLATEAU clinical study activities, and for general corporate purposes.  **[863894_9c0b793571da4d70bc46727eaf9d5ac6_0]**

Veru Prices Public Offering

- Veru Inc. has **commenced an underwritten public offering** of shares of its common stock (or pre-funded warrants to purchase common stock) and accompanying Series A and Series B warrants to purchase shares of its common stock.  **[863894_686e5a0c393a4960a175457b27ea96d1_0]** 
- The net proceeds from the proposed offering are intended to **fund the development of enobosarm**, with a primary focus on Phase 2b PLATEAU clinical study activities, as well as for working capital and other general corporate purposes.  **[863894_686e5a0c393a4960a175457b27ea96d1_0]** 
- **Canaccord Genuity LLC** and **Oppenheimer & Co. Inc.** are acting as joint book-running managers for the offering.  **[863894_686e5a0c393a4960a175457b27ea96d1_0]**

Veru Announces Proposed Public Offering

VERU (VERU)